TOKYO -- Blackstone on Wednesday announced the sale of Alinamin Pharmaceutical, a Japanese over-the-counter drugmaker it acquired in 2020, to Seoul-based private equity fund MBK Partners in a deal estimated at 350 billion yen ($2.2 billion). The sale is latest in a series of transactions by the U.S. private equity giant in the Japanese health care sector.
Pharmaceuticals
Blackstone targets health care sector in Japan push
Alinamin Pharma sale is latest in string of deals by U.S. private equity
Blackstone is accelerating the pace of its deals in the Japanese health care business, including the purchase of an over-the-counter drugmaker. (Source photos by Tomoki Mera and Jo Miyaguchi)
Read Next
Latest on Pharmaceuticals
